Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mümmler, C; Milger, K.
Biologics for severe asthma and beyond.
Pharmacol Ther. 2023; 252:108551
Doi: 10.1016/j.pharmthera.2023.108551
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Milger-Kneidinger Katrin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Advances in pathophysiological understanding and the elucidation of a type 2 inflammatory signature with interleukins 4, 5 and 13 at its center have led to the development of targeted antibody therapies that are now approved for the treatment of severe asthma. In suitable patients, these medications reduce asthma exacerbations and the necessity for oral corticosteroids, improve asthma control, quality of life and lung function. A proportion of patients with severe asthma may even achieve remission under ongoing biologic therapy. Type-2 inflammatory comorbidities are frequent in patients with severe asthma, sharing overlapping pathophysiology and may similarly respond to biologic treatment. Here, we give an overview of the six biologic therapies currently approved for severe asthma and review randomized clinical trials and real-life studies in asthma and other type-2 inflammatory diseases. We also discuss selection of biologics according to licensing criteria, asthma phenotype and biomarkers, monitoring of treatment response and proceedings in case of insufficient outcome under therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Anti-Asthmatic Agents - pharmacology, therapeutic use
- Quality of Life - administration & dosage
- Biological Products - pharmacology, therapeutic use
- Asthma - administration & dosage
- Biomarkers - administration & dosage
- Find related publications in this database (Keywords)
- Asthma
- Severe asthma
- Biologics
- Antibody
- T2
- CRSwNP
- Atopic dermatitis